New analyses of data keep hope alive for Alzheimer’s drug gantenerumab

BARCELONA – A failed phase III clinical trial for the investigational antiamyloid antibody gantenerumab in patients with Alzheimer’s disease may have had better results with a higher dose aimed at a...